1. Home
  2. ALP vs DRMA Comparison

ALP vs DRMA Comparison

Compare ALP & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Compute Corp Common Stock

ALP

Alpha Compute Corp Common Stock

N/A

Current Price

$3.22

Market Cap

5.1M

Sector

Energy

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$0.80

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALP
DRMA
Founded
N/A
2014
Country
British Virgin Islands
United States
Employees
2
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.6M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
ALP
DRMA
Price
$3.22
$0.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
83.6K
★ 5.8M
Earning Date
11-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18,642.27
N/A
Revenue Next Year
$25.41
$650.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.60
52 Week High
$5.79
$4.66

Technical Indicators

Market Signals
Indicator
ALP
DRMA
Relative Strength Index (RSI) 48.06 40.37
Support Level $2.78 $0.60
Resistance Level $5.79 $1.41
Average True Range (ATR) 0.46 0.13
MACD -0.08 0.01
Stochastic Oscillator 23.77 30.65

Price Performance

Historical Comparison
ALP
DRMA

About ALP Alpha Compute Corp Common Stock

Alpha Compute Corp owns and operates AI infrastructure powered by confidential compute and hardware-level encryption. Alpha Compute's GPU assets deliver privacy-preserving computation to partners and applications including Telegram, Animoca Brands, and Midnight Network.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: